

COPY FROM PARENT



Substitute for form 1449A-B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/187,215 10/649,378
		Filing Date	June 27, 2002 August 26, 2003
		First Named Inventor	Alan M. Fogelman
		Group Art Unit	1614
		Examiner Name	Unassigned
		Attorney Docket Number	407T-011220US-407T-911270US
		Date Submitted	February 5, 2003

Nov. 11, 2003

Class / Subclass

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
JRL	01	3,767,040		Tushaus	10-23-1973
JRL	02	4,155,913		Hellerbach et al.	05-22-1979
JRL	03	4,643,988		Segrest et al.	02-17-1987
JRL	04	5,721,138		Lawn	02-24-1998
JRL	05	5,733,549		Yamada et al.	03-31-1998
JRL	06	5,814,467		Curtiss et al.	09-29-1998
JRL	07	5,854,238		Kempen	12-29-1998
JRL	08	6,037,323		Dasseux et al.	03-14-2000
JRL	09	6,086,918		Stern et al.	07-11-2000

Class / Subclass

Examiner Initials		Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	<i>Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear</i>	T
		Office	Number	Kind Code (if known)				
JRL	10	WO	97/36927	A1	Boffelli et al.	10-09-1997	<u> </u>	
JRL	11	WO	99/47566	A1	The UAB Research Foundation	09-23-1999	<u> </u>	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
JRL	12	ANANTHARAMAIAH (1986) "Synthetic Peptide Analogs of Appolipoproteins." <i>Methods in Enzymology</i> 128:627-647	
JRL	13	ANANTHARAMAIAH and GARBER (1996) "Chromatographic Methods for Quantitation of Apolipoprotein A-I." <i>Meth. Enzymol.</i> 263: 267-282	
JRL	14	ANANTHARAMAIAH et al. (1985) "Studies of Synthetic Peptide of the Amphipathic Helix." <i>The Journal of Biological Chemistry</i> 260:10248-10255	
JRL	15	ANANTHARAMAIAH et al. (1990) "Use of Synthetic Peptide Analogues to Localize Lecithin: Cholesterol Acyltransferase Activating Domain in Apolipoprotein A-I." <i>Arteriosclerosis</i> 10:95-105	

Examiner Signature	Jeffrey E. Russell	Date Considered	April 17, 2005
--------------------	--------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known
		Application Number <u>10/167,213</u> <u>10/1649,378</u>
		Filing Date <u>June 27, 2002</u> <u>August 26, 2003</u>
		First Named Inventor <u>Alan M. Fogelman</u>
		Group Art Unit <u>1614</u>
		Examiner Name <u>Unassigned</u>
		Attorney Docket Number <u>4877-811220US 409T-911270US</u>
		Date Submitted <u>January 5, 2003</u> <u>11/11/03</u>

<i>JCL</i>	16	ANANTHARAMAIAH et al. (1993) "An Atlas of the Amphipathic Helical Domains of Human Exchangeable Plasma Apolipoproteins." Chapter. 6:109-142 In: <i>The Amphipathic Helix</i> (Epand, R. M., ed), CRC Press, Boca Raton, FL
<i>JCL</i>	17	ARMSTRONG et al. (1993) D amino acid levels in human physiological fluids, <i>Chirality</i> , 5: 375-378
<i>JCL</i>	18	BADIMON et al. (1990) "Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-fed Rabbit." <i>J. Clinical Investigation</i> 85:1234-1241
<i>JCL</i>	19	BAUER et al. (1982) "SMS 201-995: A Very Potent and Selective Octapeptide Analogue of Somatostatin with Prolonged Action" <i>Life Sciences</i> 31:1133-1140.
<i>JCL</i>	20	BOFFELLI et al. (1997) "Reconstitution and Further Characterization of the Cholesterol Transport Activity of the Small-Intestinal Brush Border Membrane" <i>Biochemistry</i> 36:10784-10792.
<i>JCL</i>	21	BOFFELLI et al. (1997) "The uptake of cholesterol at the small-intestinal brush border membrane is inhibited by apolipoproteins." <i>FEBS Letters</i> , 411: 7-11
<i>JCL</i>	22	BORHANI et al. (1999) "Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation." <i>Proc. Natl. Acad. Sci. USA.</i> 94:12291-12296
<i>JCL</i>	23	BROUILLETTE and ANANTHARAMAIAH (1995) "Structural models of human apolipoprotein A-I." <i>Biochim. Biophys. Acta</i> 1256: 103-129
<i>JCL</i>	24	BROUILLETTE et al. (2001) "Structural Models of Human Apolipoprotein A-I: A Critical Analysis and Review" <i>Biochimica et Biophysica Acta</i> 55753:1-44.
<i>JCL</i>	25	Canadian Pharmacists Association, Starlix General Monograph. http://cpa.infinetcomm.com/content/hcp/tools/cps_cnp_updates/starlix.cfm (2002)
<i>JCL</i>	26	CHUNG et al. (1985) "Studies of Synthetic Peptide Analogs of the Amphipathic Helix." <i>J. Biol. Chem.</i> 60(18): 10256-10262
<i>JCL</i>	27	DATTA et al. (2001) "Effects of Increasing Hydrophobicity on the Physical-Chemical and Biological Properties of a Class A Amphipathic Helical Peptide. <i>J Lipid Research</i> 42:1096-1104.
<i>JCL</i>	28	DAVIDSON et al. (1994) "The Influence of Apolipoprotein Structure on the Efflux of Cellular Free Cholesterol to High Density Lipoprotein." <i>J. Biol. Chem.</i> 269(37): 22975-22982
<i>JCL</i>	29	DIEDERICH et al. (2001) "Apolipoprotein AI and HDL ₃ Inhibit Spreading of Primary Human Monocytes through a Mechanism that Involves Cholesterol Depletion and Regulation of CD42." <i>Atherosclerosis</i> 159:313-324.
<i>JCL</i>	30	DOOLEY et al. (1994) "An All D-Amino Acid Opioid Peptide with Central Analgesic Activity from a Combinatorial Library" <i>Science</i> 2019-2022.

Examiner Signature	<i>Jeffrey E. Russell</i>	Date Considered	<i>April 19, 2005</i>
--------------------	---------------------------	-----------------	-----------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031


<p>Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>O I P E JC 168 NOV 14 2003 (use as many sheets as necessary)</small> </p>		Complete if Known																																	
		Application Number	104187-215 10/649,378																																
		Filing Date	June 27, 2002 AUGUST 25, 2003																																
		First Named Inventor	Alan M. Fog Iman																																
		Group Art Unit	1614																																
		Examiner Name	Unassigned																																
		Attorney Docket Number	407T-011220US 407T-911270US																																
Date Submitted	November 11, 2003																																		
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 10%;">#</td> <td style="width: 90%;">Reference Cited</td> </tr> <tr> <td>32</td> <td>DUNLOP and NEIDLE (1997) "The Orgion and Turnover of D-Serine in Brain." <i>Biochemical and Biophysical Research Communication</i> 235:26-30</td> </tr> <tr> <td>33</td> <td>EHARA et al. (2001) "Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes." <i>Circulation</i> 103:1955-1960</td> </tr> <tr> <td>34</td> <td>EPAND et al. (1987) "Studies Synthetic Peptide Analog of the Amphipathic Helix" <i>J. Biol. Chem.</i> 262(19): 9389-9396</td> </tr> <tr> <td>35</td> <td>FIELD et al. (2001) "Gene expression of sterol regulatory element-binding proteins in hamster small intestine." <i>Journal of Lipid Research</i> 42:1-9</td> </tr> <tr> <td>36</td> <td>FIELDING and FIELDING (1995) "Molecular physiology of reverse cholesterol transport." <i>J. Lipid Res.</i> 36: 211-228</td> </tr> <tr> <td>37</td> <td>FIELDING et al. (1972) "A Protein of Lecithin: Cholester Acyltransferase." <i>Biochem. Biophys. Res. Comm.</i> 46(2):1493-1498</td> </tr> <tr> <td>38</td> <td>FRICKER et al. (1995) "Enteral Absorption of Octreotide: Modulation of Intestinal Permeability by Distinct Carbohydrates" <i>The Journal of Pharmacology and Experimental Therapeutics</i> 274:826-832</td> </tr> <tr> <td>39</td> <td>FUESSL et al. (1987) "Oral Absroption of the Somatostatin Analogue SMS 201-995: Theoretical and Practial Implications" <i>Clinical Science</i> 72: 255-257.</td> </tr> <tr> <td>40</td> <td>GARBER et al. (1992) "Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties." <i>Arteriosclerosis and Thrombosis</i>, 12(8): 886-894</td> </tr> <tr> <td>41</td> <td>GARBER et al. (1997) <i>Circulation</i> 96-I-490</td> </tr> <tr> <td>42</td> <td>GARBER et al. (1999) "Protection against Atherosclerosis in Mice by a Synthetic Class A Amphipathic Peptide Analog of Apolipoprotein A-I." <i>Circulation</i> 100: 2838</td> </tr> <tr> <td>43</td> <td>GARBER et al. (2001) "A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis." <i>Journal of Lipid Research</i> 42:-545-552</td> </tr> <tr> <td>44</td> <td>GONG et al. (1994) "Structural and functional properties of human and mouse apolipoprotein A-I." <i>Biochim. Biophys. Acta</i> 1213:335-342</td> </tr> <tr> <td>45</td> <td>GURFINKEL et al. (2002) "Influenza Vaccine Pilot Study in Acute Coronary Syndromes and Planned Percutaneous Coronary Interventions. The FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study" <i>Circulation</i> 105:2143-2147.</td> </tr> <tr> <td>46</td> <td>HAMASE et al. (2001) "Determination of Free D-Proline and D-Leucine in the Brains of Mutant Mice Lacking D-Amino Acid Oxidase Activity" <i>Analytical Biochemistry</i> 298:253-258.</td> </tr> </table>				#	Reference Cited	32	DUNLOP and NEIDLE (1997) "The Orgion and Turnover of D-Serine in Brain." <i>Biochemical and Biophysical Research Communication</i> 235:26-30	33	EHARA et al. (2001) "Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes." <i>Circulation</i> 103:1955-1960	34	EPAND et al. (1987) "Studies Synthetic Peptide Analog of the Amphipathic Helix" <i>J. Biol. Chem.</i> 262(19): 9389-9396	35	FIELD et al. (2001) "Gene expression of sterol regulatory element-binding proteins in hamster small intestine." <i>Journal of Lipid Research</i> 42:1-9	36	FIELDING and FIELDING (1995) "Molecular physiology of reverse cholesterol transport." <i>J. Lipid Res.</i> 36: 211-228	37	FIELDING et al. (1972) "A Protein of Lecithin: Cholester Acyltransferase." <i>Biochem. Biophys. Res. Comm.</i> 46(2):1493-1498	38	FRICKER et al. (1995) "Enteral Absorption of Octreotide: Modulation of Intestinal Permeability by Distinct Carbohydrates" <i>The Journal of Pharmacology and Experimental Therapeutics</i> 274:826-832	39	FUESSL et al. (1987) "Oral Absroption of the Somatostatin Analogue SMS 201-995: Theoretical and Practial Implications" <i>Clinical Science</i> 72: 255-257.	40	GARBER et al. (1992) "Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties." <i>Arteriosclerosis and Thrombosis</i> , 12(8): 886-894	41	GARBER et al. (1997) <i>Circulation</i> 96-I-490	42	GARBER et al. (1999) "Protection against Atherosclerosis in Mice by a Synthetic Class A Amphipathic Peptide Analog of Apolipoprotein A-I." <i>Circulation</i> 100: 2838	43	GARBER et al. (2001) "A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis." <i>Journal of Lipid Research</i> 42:-545-552	44	GONG et al. (1994) "Structural and functional properties of human and mouse apolipoprotein A-I." <i>Biochim. Biophys. Acta</i> 1213:335-342	45	GURFINKEL et al. (2002) "Influenza Vaccine Pilot Study in Acute Coronary Syndromes and Planned Percutaneous Coronary Interventions. The FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study" <i>Circulation</i> 105:2143-2147.	46	HAMASE et al. (2001) "Determination of Free D-Proline and D-Leucine in the Brains of Mutant Mice Lacking D-Amino Acid Oxidase Activity" <i>Analytical Biochemistry</i> 298:253-258.
#	Reference Cited																																		
32	DUNLOP and NEIDLE (1997) "The Orgion and Turnover of D-Serine in Brain." <i>Biochemical and Biophysical Research Communication</i> 235:26-30																																		
33	EHARA et al. (2001) "Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes." <i>Circulation</i> 103:1955-1960																																		
34	EPAND et al. (1987) "Studies Synthetic Peptide Analog of the Amphipathic Helix" <i>J. Biol. Chem.</i> 262(19): 9389-9396																																		
35	FIELD et al. (2001) "Gene expression of sterol regulatory element-binding proteins in hamster small intestine." <i>Journal of Lipid Research</i> 42:1-9																																		
36	FIELDING and FIELDING (1995) "Molecular physiology of reverse cholesterol transport." <i>J. Lipid Res.</i> 36: 211-228																																		
37	FIELDING et al. (1972) "A Protein of Lecithin: Cholester Acyltransferase." <i>Biochem. Biophys. Res. Comm.</i> 46(2):1493-1498																																		
38	FRICKER et al. (1995) "Enteral Absorption of Octreotide: Modulation of Intestinal Permeability by Distinct Carbohydrates" <i>The Journal of Pharmacology and Experimental Therapeutics</i> 274:826-832																																		
39	FUESSL et al. (1987) "Oral Absroption of the Somatostatin Analogue SMS 201-995: Theoretical and Practial Implications" <i>Clinical Science</i> 72: 255-257.																																		
40	GARBER et al. (1992) "Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties." <i>Arteriosclerosis and Thrombosis</i> , 12(8): 886-894																																		
41	GARBER et al. (1997) <i>Circulation</i> 96-I-490																																		
42	GARBER et al. (1999) "Protection against Atherosclerosis in Mice by a Synthetic Class A Amphipathic Peptide Analog of Apolipoprotein A-I." <i>Circulation</i> 100: 2838																																		
43	GARBER et al. (2001) "A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis." <i>Journal of Lipid Research</i> 42:-545-552																																		
44	GONG et al. (1994) "Structural and functional properties of human and mouse apolipoprotein A-I." <i>Biochim. Biophys. Acta</i> 1213:335-342																																		
45	GURFINKEL et al. (2002) "Influenza Vaccine Pilot Study in Acute Coronary Syndromes and Planned Percutaneous Coronary Interventions. The FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study" <i>Circulation</i> 105:2143-2147.																																		
46	HAMASE et al. (2001) "Determination of Free D-Proline and D-Leucine in the Brains of Mutant Mice Lacking D-Amino Acid Oxidase Activity" <i>Analytical Biochemistry</i> 298:253-258.																																		

Examiner Signature	Jeffrey E. Russell	Date Considered	April 14, 2005
--------------------	--------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CCOPY FROM PARENT

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031



Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known
		Application Number <u>10/107,215</u> <u>10/649,378</u>
		Filing Date <u>June 27, 2002</u> <u>August 26, 2003</u>
		First Named Inventor <u>Alan M. F gelman</u>
		Group Art Unit <u>1614</u>
		Examiner Name <u>Unassigned</u>
		Attorney Docket Number <u>407T-911220US 407T-911270US</u>
		Date Submitted <u>February 5, 2003</u> <u>11/11/03</u>
47	HARDY et al. (2001) "An Automated High-Performance Liquid Chromatography Procedure for the Quantitation of L- and D-Amino Acids by Means of Stepwise Precolumn Derivatization" <i>Analytical Biochemistry</i> 291:297-299.	
48	HASHIMOTO et al. (2000) "Improvement of intestinal absorption of peptides: absorption of B1-Phe monoglycosylated insulin to rat intestinal brush-border membrane vesicles." <i>J. Pharmaceutics & Therapeutics</i> 50(2):197-204	
49	HAUSER et al. (1998) "Identification of a Receptor Mediating Absorption of Dietary Cholesterol in the Intestine" <i>Biochemistry</i> 178423-17850.	
50	HAYRY et al. "Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat." <i>FASEB J.</i> 9(13):1336-1344 (1995)	
51	HYKA et al. (2001) "Apolipoprotein A-I Inhibits the Production of Interleukin-1beta and Tumor Necrosis Factor-alpha by Blocking Contact-Mediated Activation of Monocytes by T Lymphocytes." <i>Blood</i> 97:2381-2389.	
52	JOHNSON et al. (1991) "Cholesterol transport between cells and high-density lipoproteins." <i>Biochim. Biophys. Acta</i> 1085: 273-298	
53	JONAS (1991) "Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins." <i>Biochim. Biophys. Acta</i> 1084: 205-220	
54	JONAS (2000) Lecithin cholesterol acyltransferase." <i>Biochim. Biophys. Acta</i> 1529: 245-256	
55	JONES et al. (1992) "Computer Programs to Identify and Classify Amphipathic alpha Helical Domains" <i>Journal of Lipid Research</i> 33:287-296.	
56	KIGASAWA et al. (1995) "Inhibition of corneal ulceration by tetrapeptidyl hydroxamic acid." <i>Jap. J. Ophthalmology</i> 39(1):35-42	
57	KREIGER (1999) "Charting The Fate of the "Good Cholesterol": Identification and Characterization of the High-Density Lipoprotein Receptor Sr-Bi." <i>Ann Rev. Biochem.</i> 68: 523-558	
58	KULLMAN et al. (1999) "Evaluation of the Enantiomeric Composition of Amino Acids in Tobacco" <i>Chirality</i> 11:669-673.	
59	SENIOR (1999) "New options developed for needle-free drug delivery" <i>Lancet</i> Sept. 25, 1999	
60	LEVI et al. (2000) "A retro-inverso minantibody with anti-HIV activity." <i>Aids Res. & Human Retrovirus</i> 16(1):59-65.	
61	LUNDIN et al. (1986) "Absorption of Intragastrically Administered DDAVP in Conscious Dogs" <i>Life Sciences</i> 38:703-709.	
62	MAN et al. (1987) D-aspartate in human brain." <i>J Neurochem</i> 48:510-515	

Examiner Signature	Jeffrey E. Russell	Date Considered	April 14, 2005
--------------------	--------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/107,215 10/1649,378
		Filing Date	June 27, 2002 August 26, 2003
		First Named Inventor	Alan M. Fogelman
		Group Art Unit	1614
		Examiner Name	Unassigned
		Attorney Docket Number	4077-91122003 4077-91127003
		Date Submitted	February 5, 2003 4/14/03



RL	63	MERRIFIELD et al. (1995) "Retro and Retroenantiomeric Analogs of Cecropin-Melittin Hybrids" <i>Proc Natl Acad Sci USA</i> 92: 3449-3453.
RL	64	MISHRA et al. (1994) "Interaction of Synthetic Peptide Analogs of the Class A" <i>J. Biol. Chem.</i> 269: 7185-7191
RL	65	MISHRA et al. (1995) "Effect of the Arrangement of Tandem Repeating Units of Class A Amphipathic alpha-Helices on Lipid Interaction." <i>J. Biol. Chem.</i> 270: 1602-1611
RL	66	MISHRA et al. (1998) "Studies of Synthetic Peptides of Human Apolipoprotein A-I Containing Tandem Amphipathic alpha-Helices" <i>Biochemistry</i> 37: 10313-10324
RL	67	MOR et al. (1992) Enter a new post-translational modification: D-amino acids in gene-encoded peptides, <i>TIBS</i> , 17: 481-485
RL	68	NAGATA et al. (1994) "Distribution of free D-serine in vertebrate brains", <i>Brain Res.</i> , 634: 291-295.
RL	69	NAGATA et al. (1995) "Free D-serine concentration in normal and Alzheimer human brain", <i>Brain Res. Bull.</i> , 38(2): 181-183
RL	70	NAVAB et al. (2000) "Normal high-density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1." <i>J. Lipid Res.</i> 41: 1481-1494
RL	71	NAVAB et al. (2000) "Normal high-density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3." <i>J. Lipid Res.</i> 41: 1495-1508
RL	72	NAVAB et al. (2002) "Oral Administration of an Apo A-I Mimetic Peptide Synthesized from D-Amino Acids Dramatically Reduces Atherosclerosis in Mice Independent of Plasma Cholesterol" <i>Circulation</i> 105: 290-292.
RL	73	NOMOTO et al. (1998) "Improved intestinal absorption of peptide drugs by Glycosylation: Transport of Tetrapeptide by the Sodium Ion-Dependent D-Glucose Transporter." <i>J. Pharmaceutics Science</i> 87(3):326-332.
RL	74	OHTANI et al. (1995) Age-related changes in D-aspartic acid of rat teeth, <i>Growth Develop. & Aging</i> , 59: 55-61
RL	75	ORAM and YOKOYAMA (1996) "Apolipoprotein-mediated removal of cellular cholesterol and phospholipids." <i>J. Lipid Res.</i> 37: 2473-2491
RL	76	OWENS et al. (1990) "Apolipoprotein A-I and its Amphipathic Helix Peptide Analogue Inhibit Human Immunodeficiency Virus-Induced Syncytium Formation" <i>J Clin Invest</i> 86: 1142-1150.
RL	77	PAIGEN et al. (1990) "Atherosclerosis Susceptibility Differences among Progenitors of Recombinant Inbred Strains of Mice." <i>Arteriosclerosis</i> 10: 316-323
RL	78	PALGUNACHARI et al. (1996) "Only the Two End Xeleses of Eight Tandem Amphipathic Helical Domains of Human Apo A-I Have Significant Lipid Affinity." <i>Arteriosclerosis, Thrombosis, & Vascular Biology</i> 16: 328-338

Examiner Signature	Jeffrey E. Russell	Date Considered	April 18, 2003
--------------------	--------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PATENT

Substitute for form 1449A-B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/167,215	10/649,378
Filing Date	June 27, 2002	August 26, 2003
First Named Inventor	Alan M. F gelman	
Group Art Unit	1614	
Examiner Name	Unassign d	
Attorney Docket Number	407T-911220US 407T-911270US	
Date Submitted	February 5, 2003	4/11/03

79	PANIZZUTTI et al. (2001) "A New Strategy to Decrease N-methyl-D-aspartate (NMDA) Receptor Coactivation: Inhibition of D-serine Synthesis by Converting Serine Racemase into an Eliminase" <i>PNAS</i> 98:5294-5299.
80	PAPPENHEIMER et al. (1994) "Intestinal Absorption and Excretion of Octapeptides Composed of D Amino Acids" <i>Proc Natl Acad Sci USA</i> 91: 1942-1945.
81	PAPPENHEIMER et al. (1997) "Absorption and Excretion of Undegradable Peptides: Roles of Lipid Solubility and Net Charge." <i>J. Pharmacology & Experimental Therapeutics</i> 280(1):292-300
82	PATSZTY et al. (1994) "Apolipoprotein AI Transgene Corrects Apolipoprotein E Deficiency-induced Atherosclerosis in Mice." <i>J. Clinical Investigation</i> 94:899-903
83	PENG et al. (2001) "Effects of L-glutamate, D-aspartate, and Monensin on Glycolytic and Oxidative Glucose Metabolism in Mouse Astrocyte Cultures: Further Evidence that Glutamate Uptake is Metabolically Driven by Oxidative Metabolism" <i>Neurochemistry International</i> 38:437-443.
84	PHARMALICENSING (27 Jan. 2001) Esperion Builds a Novel Peptides Program (2 pages)
85	PHARMALICENSING (28 Jan. 2001) Multiple Peptide Systems Forms Joint Venture With Elan
86	PHARMALICENSING (28 Jan. 2001) Unigene to Receive Patent for Delivery of Peptide Pharmaceuticals (2 pages)
87	PHILIPS et al. (1993) "Plasma Lipoproteins and Progression of Coronary Artery Disease Evaluated by Angiography and Clinical Events." <i>Circulation</i> 88: 2762-2770
88	PILONE (2000) D-amino acid oxidase: new findings. <i>CMLS, Cell. Mol. Life Sci.</i> , 57: 1732-1747
89	PLUMP et al. (1994) "Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses sttherosclerosis in the apolipoprotein E-deficient mouse." <i>Proc. Natl. Acad. Sci. USA</i> 91:9607-9611
90	PURDUE NEWS (October 2000) 'Microspheres' Offer Promise for Oral Drug Delivery (3 pages)
91	PURDUE NEWS (September 12, 1997) New Oral Insulin Delivery System Shows Promise (3 pages)
92	REUBSAET et al. (1999) "Qualitative and quantitative aspects of the degradation of several tripeptides derived from the antitumour peptide antagonist [Arg ⁶ , D-Trp ^{7,8} , MePhe ⁹] substance P(6-11)." <i>J. Pharmaceut. & Biomed Analysis</i> 19(3-4):277-284
93	RUBIN et al. (1991) "Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI." <i>Nature</i> 353:265-267

Examiner Signature	Jeffrey E. Russel	Date Considered	April 14, 2003
--------------------	-------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM EXAMINER

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/187,215 10/1649378
(use as many sheets as necessary)		Filing Date	June 27, 2002 August 26, 2003
		First Named Inventor	Alan M. F g Iman
		Group Art Unit	1614
		Examiner Name	Unassigned
		Attorney Docket Number	407T-9TT220US 407T-911270US
		Date Submitted	February 5, 2003 4/14/03

94	SEGREST et al. (1974) "A Molecular Theory of Lipid-Protein Interaction in the Plasma Lipoproteins." <i>FEBS Lett.</i> 38: 247-253
95	SEGREST et al. (1990) "Amphipathic Helix Motif: Classes and Properties." <i>Proteins: Structure, Function and Genetics</i> 8: 103-117
96	SEGREST et al. (1992) "The Amphipathic Helix in the Exchangeable Apolipoproteins: A Review of Secondary Structure and Function" <i>J Lipid Research</i> 33:141-166.
97	SEGREST et al. (1994) "The Amphipathic alpha Helix: A Multifunctional Structural Motif in Plasma Apolipoproteins." <i>Adv. Prot. Chem.</i> 45: 303-369
98	SEGREST et al. (2000) "Structure and function of apolipoprotein A-I and high-density lipoprotein." <i>Current Opin. Lipidol.</i> 11:105-115
99	SHAH et al. (1998) "Effect of Recombinant Apolipoprotein A-I _{Milano} on Aortic Atherosclerosis in Apolipoprotein E-Deficient Mice." <i>Circulation</i> 97:780-785.
100	SINGH et al. (2000) "Innate Defences Against Viraemia" <i>Rev Med Virol</i> 10:395-403.
101	SPRECHER et al. (1993) "The Low HDL Cholesterol/ High Triglyceride Trait." <i>Arterioscler. Thromb.</i> 13: 495-504
102	SRINIVAS et al. (1990) "Antiviral Effects of Apolipoprotein A-I and Its Synthetic Amphipathic Peptide Analogs" <i>Virology</i> 176:48-57.
103	Starlix MC—Amino Acid Fact Sheet. http://www.starlix.com/media_center/content/pages/amino.htm . (2002)
104	SU AND AMIDON (1995) Investigation into the intestinal metabolism of [D-Ala] peptide T amide: implication for oral drug delivery, <i>Biochim et Biophys.</i> , 1245: 62-68
105	THE WALL STREET JOURNAL (Jan 13, 2000) "Emisphere technologies develops oral Heparin"
106	TSAI et al. (1998) D-serine added to antipsychotics for the treatment of schizophrenia. <i>Biol. Psychiatry</i> , 44: 1081-1089
107	TSAO et al. (2001) "Hibernation-induction Peptide and Cell Death: [D-Ala ² , D-Leu ⁵]enkephalin Blocks Bax-related Apoptotic Processes" <i>European Journal of Pharmacology</i> 428:149-151.
108	TSIMIKAS et al. (2001) "Measuring Circulating Oxidized Low-Density Lipoprotein to Evaluate Coronary Risk." <i>Circulation</i> 103:1930-1932
109	VAN LENTEN et al. (2001) <i>Circulation</i> 103:2283-2288.
110	VENKATACHALAPATHI et al. (1993) "Effect of End Group Blockage on the Properties of a Class A Amphipathic Helical Peptid." <i>Proteins:Structure, Function, and Genetics</i> 15:349-359.
111	WILSON et al. (1988) "High Density Lipoprotein Cholesterol and mortality: The Framingham Heart Study." <i>Arteriosclerosis</i> 8: 737-741

Examiner Signature	Jeffrey E. Russell	Date Considered	April 17, 2005
--------------------	--------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPYRIGHT ELEMENT

(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/187,216 10/1649,378
		Filing Date	June 27, 2002 August 26, 2003
		First Named Inventor	Alan M. Fogelman
		Group Art Unit	1614
		Examiner Name	Unassigned
		Attorney Docket Number	407T-911220US 407T-911270US
		Date Submitted	February 5, 2003 → 11/11/03
OIE NOV 16 2003 PATENT & TRADEMARK OFFICE	112	YANCEY et al. (1995) "Efflux of Cellular Cholesterol and Phospholipid to Lipid-free Apolipoproteins and Class A Amphiphatic Peptides." <i>Biochemistry</i> , 34: 7955-7965	

Examiner Signature	Jeffrey E. Russell	Date Considered	April 14, 2005
--------------------	--------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/P-10

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/649,378
Filing Date	August 25, 2003
First Named Inventor	Alan M. Fogelman
Group Art Unit	1614
Examiner Name	Jeffrey E. Russel
Attorney Docket Number	407T-911250US
Date Submitted	May 27, 2004

U.S. PATENT DOCUMENTS					Class 15 Sub-53	
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
JER	1	6,664,230		Fogelman et al.	12/16/2003	S14 / 13
JER	2	5,344,822		Levine et al.	9/6/1994	S14 / 13

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS								
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T	

Examiner Signature	Jeffrey E. Russel	Date Considered	April 14, 2005
--------------------	-------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.